Global Human Adiponectin Antibody Market Size, Share and Trends Analysis Report, By Disease (Type 2 Diabetes, Obesity, and Cardiovascular Disease), By End User (Hospital, Clinic, and Others), Forecast (2022-2028)

The human adiponectin antibody market is anticipated to grow at a significant CAGR of 11% during the forecast period (2022-2028). Adiponectin is a hormone that has the potential to protect against diabetes. This hormone works against atherosclerosis. Various experiments and studies have proved that a decreased level of adiponectin paves the way for the development of type 2 diabetes, obesity, and cardiovascular disease. Trials done on rodent models have shown that this antibody is a physiological regulator of insulin and cardiovascular homeostasis. Pharmacology and dietary interventions are suggested to induce adipose tissue in secreting adiponectin. In the coming time, the strategy of inducing adipose tissue can act as a potential therapeutic approach to treat certain metabolic diseases. Adiponectin receptors have two isoforms that help mediate Adiponectin effects. Muscles of the skeletal and liver are directly affected by adiponectin. It has varying molecular weight forms. Endoplasmic reticulum proteins such as oxidoreductase 1-α, glucose-regulated protein 94 have been found to be involved in the secretion of adiponectin complexes.

 

The global human adiponectin antibody market is segmented by disease and by end-user. Based on disease, the market is sub-segmented into type 2 diabetes, obesity, and cardiovascular disease. Based on end-user, the market is sub-segmented into hospitals, clinics, and others. Obesity is a cause of concern for every individual as it leads to various diseases such as diabetes, cardiovascular diseases, stroke, etc. health experts are of the view that obesity can even reduce the normal span of life. As per World Health Organization, in the year 2020, around 39 million children who are under the age of 5 were overweight.

 

Cardiovascular diseases are of many types such as coronary artery disease, cerebrovascular disease, peripheral arterial disease, and rheumatic heart disease. In the case of coronary artery disease, a deposit of cholesterol takes place in the wall of the artery. These arteries are responsible to supply blood from the heart to various other organs of the body. When cholesterol deposit happens in the walls of the artery, the heart suffers a strain in pumping blood into other organs. If this condition prevails for a long time, it could be life-threatening. As per the center for disease control and prevention of the United States, every year around 805,000 people suffer a heart attack in the US.

 

 

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Disease
  • By End-User
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Thermo Fisher Scientific Inc., Abnova Corp., Abcam plc, Novus Biologicals.

 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

 

Human Adiponectin Antibody Market Report By Segment

By Disease

• Type 2 Diabetes
• Obesity
• Cardiovascular Disease

By End-User

• Hospital
• Clinic
• Others

 

Human Adiponectin Antibody Market Report By Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa